MX2021015352A - Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal. - Google Patents
Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal.Info
- Publication number
- MX2021015352A MX2021015352A MX2021015352A MX2021015352A MX2021015352A MX 2021015352 A MX2021015352 A MX 2021015352A MX 2021015352 A MX2021015352 A MX 2021015352A MX 2021015352 A MX2021015352 A MX 2021015352A MX 2021015352 A MX2021015352 A MX 2021015352A
- Authority
- MX
- Mexico
- Prior art keywords
- fabry disease
- renal impairment
- patients
- methods
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Se proporcionan métodos para al tratamiento de la enfermedad de Fabry en un paciente que tiene insuficiencia renal; determinados métodos comprenden administrar al paciente de aproximadamente 100 mg a aproximadamente 300 mg de equivalente de base libre de migalastat o sal del mismo a una frecuencia mayor de una vez cada dos días, tal como una vez cada cuatro o siete días; determinados métodos comprenden medir la liso-Gb3 y/o el migalastat en una o más muestras de plasma del paciente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962859904P | 2019-06-11 | 2019-06-11 | |
| PCT/US2020/037174 WO2020252129A1 (en) | 2019-06-11 | 2020-06-11 | Methods of treating fabry disease in patients having renal impairment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021015352A true MX2021015352A (es) | 2022-04-06 |
Family
ID=71950725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015352A MX2021015352A (es) | 2019-06-11 | 2020-06-11 | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220313670A1 (es) |
| EP (1) | EP3982962A1 (es) |
| JP (1) | JP2022536687A (es) |
| KR (1) | KR20220019796A (es) |
| CN (1) | CN114423427A (es) |
| AR (1) | AR120055A1 (es) |
| AU (1) | AU2020291002A1 (es) |
| BR (1) | BR112021024886A2 (es) |
| CA (1) | CA3141226A1 (es) |
| CL (1) | CL2021003280A1 (es) |
| EA (1) | EA202290024A1 (es) |
| IL (1) | IL288677A (es) |
| MX (1) | MX2021015352A (es) |
| TW (1) | TW202112372A (es) |
| WO (1) | WO2020252129A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3457135A1 (en) | 2006-05-16 | 2019-03-20 | Amicus Therapeutics, Inc. | Treatment options for fabry disease |
| PL3470077T3 (pl) | 2008-02-12 | 2021-04-06 | Amicus Therapeutics, Inc. | Sposób przewidywania odpowiedzi na leczenie chorób chaperonami farmakologicznymi |
| KR20240017112A (ko) | 2017-05-30 | 2024-02-06 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 신장 손상을 갖는 파브리 환자를 치료하는 방법 |
| EP3749307A1 (en) | 2018-02-06 | 2020-12-16 | Amicus Therapeutics, Inc. | Use of migalastat for treating fabry disease in pregnant patients |
| CA3147055A1 (en) | 2019-08-07 | 2021-02-11 | Elfrida Benjamin | Methods of treating fabry disease in patients having a mutation in the gla gene |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| MX2009010557A (es) | 2007-03-30 | 2009-11-19 | Amicus Therapeutics Inc | Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas. |
| WO2008134628A2 (en) * | 2007-04-26 | 2008-11-06 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| PL3470077T3 (pl) | 2008-02-12 | 2021-04-06 | Amicus Therapeutics, Inc. | Sposób przewidywania odpowiedzi na leczenie chorób chaperonami farmakologicznymi |
| CN103974619B (zh) * | 2011-03-11 | 2017-02-15 | 阿米库斯治疗学公司 | 治疗法布里病的给药方案 |
| US20190183869A1 (en) * | 2016-07-19 | 2019-06-20 | Amicus Therapeutics, Inc. | Treatment of fabry disease in ert-naïve and ert-experienced patients |
| CN117959455A (zh) * | 2017-01-05 | 2024-05-03 | 波塔力克斯有限公司 | 植物重组人类α-半乳糖苷酶制备治疗法布里病的药品的用途 |
| AR111971A1 (es) * | 2017-05-30 | 2019-09-04 | Amicus Therapeutics Inc | Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal |
| KR20240017112A (ko) * | 2017-05-30 | 2024-02-06 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 신장 손상을 갖는 파브리 환자를 치료하는 방법 |
-
2020
- 2020-06-11 WO PCT/US2020/037174 patent/WO2020252129A1/en unknown
- 2020-06-11 EP EP20751716.0A patent/EP3982962A1/en active Pending
- 2020-06-11 AU AU2020291002A patent/AU2020291002A1/en active Pending
- 2020-06-11 JP JP2021573404A patent/JP2022536687A/ja active Pending
- 2020-06-11 AR ARP200101648A patent/AR120055A1/es unknown
- 2020-06-11 CN CN202080042938.3A patent/CN114423427A/zh active Pending
- 2020-06-11 EA EA202290024A patent/EA202290024A1/ru unknown
- 2020-06-11 BR BR112021024886A patent/BR112021024886A2/pt unknown
- 2020-06-11 CA CA3141226A patent/CA3141226A1/en active Pending
- 2020-06-11 MX MX2021015352A patent/MX2021015352A/es unknown
- 2020-06-11 KR KR1020227000878A patent/KR20220019796A/ko unknown
- 2020-06-11 US US17/618,277 patent/US20220313670A1/en active Pending
- 2020-06-11 TW TW109119640A patent/TW202112372A/zh unknown
-
2021
- 2021-12-05 IL IL288677A patent/IL288677A/en unknown
- 2021-12-09 CL CL2021003280A patent/CL2021003280A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202112372A (zh) | 2021-04-01 |
| AU2020291002A1 (en) | 2022-01-06 |
| EA202290024A1 (ru) | 2022-03-14 |
| IL288677A (en) | 2022-02-01 |
| BR112021024886A2 (pt) | 2022-01-25 |
| KR20220019796A (ko) | 2022-02-17 |
| CN114423427A (zh) | 2022-04-29 |
| AR120055A1 (es) | 2022-02-02 |
| CA3141226A1 (en) | 2020-12-17 |
| US20220313670A1 (en) | 2022-10-06 |
| EP3982962A1 (en) | 2022-04-20 |
| WO2020252129A1 (en) | 2020-12-17 |
| CL2021003280A1 (es) | 2022-10-07 |
| JP2022536687A (ja) | 2022-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021015352A (es) | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal. | |
| MX2019014410A (es) | Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| MX2018001435A (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
| CL2018001677A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| EA200971053A1 (ru) | Способы лечения кожных язв | |
| PH12020551597A1 (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
| WO2014100071A3 (en) | Substituted pyrrolopyrimidines as hdm2 inhibitors | |
| MX2023005455A (es) | Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil. | |
| CR20220215A (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
| AU2018326364A1 (en) | Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease | |
| CR20220216A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
| MX2020011453A (es) | Combinaciones para tratar el cancer. | |
| SE0300098D0 (sv) | Use of cyclin D1 inhibitors | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| CY1118486T1 (el) | Λαπατινιμπη για τη θεραπεια του καρκινου | |
| MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
| TW200719903A (en) | Compositions for the treatment of neoplasms | |
| EA202090558A1 (ru) | Схемы лечения | |
| WO2004006849A3 (en) | Combinations of drugs for the treatment of neoplasms | |
| MX2022006052A (es) | Inhibidores de la caspasa 6 y usos de los mismos. | |
| ATE502637T1 (de) | Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum | |
| CL2023000296A1 (es) | Uso de dexpramipexol para el tratamiento del asma moderado a grave | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| MX2019004200A (es) | Terapia de combinacion. | |
| EP4245366A3 (en) | Migalastat for treating fabry patients having renal impairment |